Evidence map›Paper›PMID 38034081›Full record

ArticleClinical & translational immunology2023

Changes in immune cell populations following KappaMab, lenalidomide and low-dose dexamethasone treatment in multiple myeloma.

Samuel E Norton, Tiffany Khong, Malarmathy Ramachandran, Andrew J Highton, Kirsten A Ward-Hartstonge, Jake Shortt, Andrew Spencer, Roslyn A Kemp

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical & translational immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Samuel E NortonNanix Limited Dunedin New Zealand.
Tiffany KhongMyeloma Research Group, Australian Centre for Blood Diseases Alfred Hospital-Monash University Melbourne VIC Australia.
Malarmathy RamachandranMyeloma Research Group, Australian Centre for Blood Diseases Alfred Hospital-Monash University Melbourne VIC Australia.
Andrew J HightonDepartment of Microbiology and Immunology University of Otago Dunedin New Zealand.
Kirsten A Ward-HartstongeDepartment of Microbiology and Immunology University of Otago Dunedin New Zealand.ORCID https://orcid.org/0000-0003-1225-0843
Jake ShorttMonash Haematology Monash Health Clayton VIC Australia.
Andrew SpencerMyeloma Research Group, Australian Centre for Blood Diseases Alfred Hospital-Monash University Melbourne VIC Australia.
Roslyn A KempDepartment of Microbiology and Immunology University of Otago Dunedin New Zealand.ORCID https://orcid.org/0000-0001-9092-1150
University of Otago · NZThe Alfred Hospital · AUDunedin Public Hospital · NZMonash Alfred Psychiatry Research centre · AUMonash Health · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Lenalidomide (LEN) is used to treat multiple myeloma (MM) and shows Methods: A cohort ( Results: We found changes in five DC and 17 T-cell populations throughout treatment. We showed an increase in activated conventional DC populations, a decrease in immature/precursor DC populations, a decrease in activated CD4 T cells and an increase in effector-memory CD4 T cells and effector CD8 T cells, indicating an activated immune response. Conclusion: These data characterise the effects of LEN, DEX, and KM treatment on non-target immune cells in MM. Treatment may support destruction of MM cells by both direct action and indirect mechanisms

Indexed as

cytometrydendritic cellKappaMablenalidomidemyelomaT cell

Identifiers

PMID38034081
PMCPMC10688504
OpenAlexW4389191579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.